Fulgent Genetics, Inc. (FLGT) Financials
FLGT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.3 billion | 139.8 million |
2023-09-30 | 1.4 billion | 96.6 million |
2023-06-30 | 1.4 billion | 91.3 million |
2023-03-31 | 1.4 billion | 107.8 million |
FLGT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 11.8 million | 11.4 million |
2023-09-30 | 5.3 million | 10.9 million |
2023-06-30 | -2.4 million | 10.3 million |
2023-03-31 | -9.9 million | 10.3 million |
FLGT Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2023-12-31 | -128.1 million |
2023-09-30 | -13.5 million |
2023-06-30 | -11.6 million |
2023-03-31 | -15.8 million |
FLGT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 424.2 million | - | 11.1 million |
2023-09-30 | 467.8 million | - | - |
2023-06-30 | 458.4 million | - | - |
2023-03-31 | 871.3 million | - | - |
FLGT Shares Outstanding
FLGT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 3.1 million | 12.0 million | 31.7 million | 10.5 million |
2023-09-30 | 4.9 million | 10.0 million | 17.5 million | 10.2 million |
2023-06-30 | 12.1 million | 9.7 million | 18.0 million | 10.7 million |
2023-03-31 | 2.0 million | 9.8 million | 21.8 million | 10.1 million |
FLGT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 70.5 million | 47.2 million |
2023-09-30 | 84.7 million | 44.8 million |
2023-06-30 | 67.9 million | 47.3 million |
2023-03-31 | 66.2 million | 47.4 million |
FLGT
Price: $20.10
52 week price:
Earnings Per Share: -5.63 USD
P/E Ratio: -11.69
Exchange: NGM
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 235500
Ebitda: -1.0 millionMarket Capitalization: 633.8 million